NCT05363319: An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Sponsor: Regeneron Pharmaceuticals. Phase: . Conditions: Non-small Cell Lung Cancer